A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
Status:
Completed
Trial end date:
2018-09-07
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of single
ascending intravenous doses of ASP1128 in healthy adult male and female subjects and multiple
ascending intravenous doses of ASP1128 in healthy adult male and female subjects and healthy
elderly male and female subjects.
This study will also evaluate the pharmacokinetics and the effect on the QT interval using
Fridericia's correction formula (QTcF) in these subjects.